Graft Versus Host Disease (GVHD) Pipeline Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Actelion, Effimune, Seres Therapeutics - Research and Markets
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.